Online inquiry

IVTScrip™ mRNA-Anti-IL23A, MK-3222(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ11780MR)

This product GTTS-WQ11780MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets IL23A gene. The antibody can be applied in Psoriasis research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_016584.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 51561
UniProt ID Q9NPF7
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL23A, MK-3222(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ11780MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ6519MR IVTScrip™ mRNA-Anti-ALCAM, CX-191(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CX-191
GTTS-WQ5547MR IVTScrip™ mRNA-Anti-CD40LG, CDP7657(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA CDP7657
GTTS-WQ6162MR IVTScrip™ mRNA-Anti-IGF1R, CP-751871(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CP-751871
GTTS-WQ9995MR IVTScrip™ mRNA-Anti-FGF23, KRN-23(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA KRN-23
GTTS-WQ1492MR IVTScrip™ mRNA-Anti-CD79B, ACD79B-VCMMAE(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA ACD79B-VCMMAE
GTTS-WQ13105MR IVTScrip™ mRNA-Anti-ACVRL1, PF-03446962(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA PF-03446962
GTTS-WQ2136MR IVTScrip™ mRNA-Anti-CGRP, ALD-403(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA ALD-403
GTTS-WQ9637MR IVTScrip™ mRNA-Anti-CD3E&TNFRSF17, JNJ-64007957(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA JNJ-64007957
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW